HC Wainwright & Co. Reiterates Buy on Novavax, Maintains $19 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Vernon Bernardino has reiterated a Buy rating on Novavax (NASDAQ:NVAX) and maintained a $19 price target.

May 13, 2024 | 9:53 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. reaffirms a Buy rating on Novavax with a $19 price target, indicating a positive outlook on the stock.
The reiteration of a Buy rating and maintenance of a $19 price target by a reputable analyst firm like HC Wainwright & Co. can positively influence investor sentiment and potentially lead to an increase in stock price in the short term. The specific mention of Novavax and the reaffirmation of the price target suggest a strong belief in the company's value and prospects.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100